# US 2016/0252533 A1 · Diagnosis and treatment of autoimmune diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0252533 A1
- Document ID: US20160252533A1
- Status: Published application
- Kind: A1
- Application number: 15/030,790
- Filed: 2014-10-17
- Published: 2016-09-01
- Earliest claimed: 2013-10-21
- Assignees: Dyax Corp.
- Applicants: Dyax Corp.
- Inventors: Daniel J. Sexton; Burt Adelman; Andrew Nixon
- Web page: https://patentgrep.com/patent/US20160252533A1

## CPC

- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 2333/745: Assays involving non-enzymic blood coagulation factors
- G01N 2333/8139: Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
- G01N 2800/065: Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
- G01N 2800/102: Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.

## Claims

### Claim 1

A method of diagnosing an autoimmune disease in a subject, the method comprising:
providing a biological sample of a subject suspected of having the autoimmune disease;
measuring a level of cleaved high molecular weight kininogen (HMWK) in the biological sample; and
identifying the subject as having or at risk for the autoimmune disease, if the level of cleaved HMWK in the biosample is elevated as compared to a control sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the autoimmune disease is rheumatoid arthritis, Crohn's disease, or ulcerative colitis.

### Claim 3 (depends on 1)

The method of claim 1, wherein the biological sample is a serum sample or a plasma sample.

### Claim 4 (depends on 1)

The method of claim 1, wherein the biological sample comprises one or more protease inhibitors, which are added to the biological sample after its collection.

### Claim 5 (depends on 1)

The method of claim 1, wherein the level of cleaved HMWK is measured by an assay that involves a binding agent specific to cleaved HMWK.

### Claim 6 (depends on 5)

The method of claim 5, wherein the binding agent is an antibody.

### Claim 7 (depends on 4)

The method of claim 4, wherein the assay is an enzyme-linked immunosorbent assay (ELISA) or an immunoblotting assay.

### Claim 8 (depends on 4)

The method of claim 4, wherein the assay is a Westernblotting assay involving LiCor detection.

### Claim 9 (depends on 1)

The method of claim 1, further comprising subjecting the subject to a treatment for the autoimmune disease.

### Claim 10 (depends on 9)

The method of claim 9, wherein the subject is administered with an effective amount of a plasma kallikrein (pKal) inhibitor.

### Claim 11

A method of monitoring development of an autoimmune disease in a subject, the method comprising:
providing a first biological sample of a subject suspected of having the autoimmune disease at a first time point;
measuring a first level of cleaved high molecular weight kininogen (HMWK) in the first biological sample;
providing a second biological sample of the subject at a second time point subsequent to the first time point;
measuring a second level of cleaved HMWK in the second biological sample; and
assessing development of the autoimmune disease in the subject based on the change of the levels of cleaved HMWK in the first and second biological samples,
wherein the second level of cleaved HMWK higher than the first level of cleaved HMWK indicates that the autoimmune disease progresses in the subject or the subject has developed or is at risk for developing the autoimmune disease.

### Claim 12 (depends on 11)

The method of claim 11, wherein the autoimmune disease is rheumatoid arthritis, Crohn's disease, or ulcerative colitis.

### Claim 13 (depends on 11)

The method of claim 11, wherein the first and second biological samples are serum samples or plasma samples.

### Claim 14 (depends on 10)

The method of claim 10, wherein the first biological sample, the second biological sample, or both comprises one or more protease inhibitors, which are added to the biological sample(s) after its collection.

### Claim 15 (depends on 11)

The method of claim 11, wherein the first or second level of cleaved HMWK is measured by an assay that involves a binding agent specific to cleaved HMWK.

### Claim 16 (depends on 15)

The method of claim 15, wherein the binding agent is an antibody.

### Claim 17 (depends on 15)

The method of claim 15, wherein the assay is an enzyme-linked immunosorbent assay (ELISA) or an immunoblotting assay.

### Claim 18 (depends on 15)

The method of claim 15, wherein the assay is a Westernblotting assay involving LiCor detection.

### Claim 19 (depends on 11)

The method of claim 11, further comprising subjecting the subject to a treatment for the autoimmune disease.

### Claim 20 (depends on 19)

The method of claim 19, wherein the subject is administered with an effective amount of a plasma kallikrein (pKal) inhibitor.

### Claim 21

A method of assessing the efficacy of a treatment for an autoimmune disease in a patient, the method comprising:
providing multiple biological samples of a patient subjected to a treatment for an autoimmune disease during the course of the treatment;
measuring the levels of high molecular weight kininogen (HMWK) in the multiple biological samples; and
assessing the efficacy of the treatment in the patient based on the change of the levels of cleaved HMWK over the course of the treatment,
wherein if the level of cleaved HMWK decreases during the course of the treatment, it indicates that the treatment is effective in the patient.

### Claim 22 (depends on 19)

The method of claim 19, wherein the autoimmune disease is rheumatoid arthritis, Crohn's disease, or ulcerative colitis.

### Claim 23 (depends on 21)

The method of claim 21, wherein the treatment involves at least one plasma kallikrein inhibitor.

### Claim 24 (depends on 21)

The method of claim 21, wherein at least one of the multiple biological samples is a serum sample or a plasma sample.

### Claim 25 (depends on 21)

The method of any of claim 21, wherein at least one of the multiple biological sample comprises one or more protease inhibitors, which are added to the sample after its collection.

### Claim 26 (depends on 21)

The method of claim 21, wherein the levels of cleaved HMWK in the multiple biological samples are measured by an assay that involves a binding agent specific to cleaved HMWK.

### Claim 27 (depends on 26)

The method of claim 26, wherein the binding agent is an antibody.

### Claim 28 (depends on 26)

The method of claim 26, wherein the assay is an enzyme-linked immunosorbent assay (ELISA) or an immunoblotting assay.

### Claim 29 (depends on 26)

The method of claim 26, wherein the assay is a Westernblotting assay involving LiCor detection.
